Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinsonâ€™s disease.
Prexaâ€™s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexaâ€™s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexaâ€™s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.
Funding Rounds (2) - $10.2MUpdate
184 High Street
Boston, MA 02110